Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK574073PMID: 34554670
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 511-12-6
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of dihydroergotamine during breastfeeding. Because it might cause adverse effects in the infant and decrease the milk supply, most authorities consider ergotamine to be contraindicated during nursing.[1-3] The manufacturer of the dihydroergotamine nasal spray recommends that nursing mother should not breastfeed during treatment and for 3 days after the last dose. Any milk that is pumped during this time should be discarded.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Davanzo R, Bua J, Paloni G, et al. Breastfeeding and migraine drugs. Eur J Clin Pharmacol. 2014;70:1313–24. [PubMed: 25217187]
- 2.
- MacGregor EA. Migraine in pregnancy and lactation. Neurol Sci. 2014;35 Suppl 1:61–4. [PubMed: 24867839]
- 3.
- Anderson PO. Migraine drug therapy during breastfeeding. Breastfeed Med. 2019;14:445–7. [PubMed: 31347910]
Substance Identification
Substance Name
Dihydroergotamine
CAS Registry Number
511-12-6
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.[Headache. 2020]A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.Albrecht D, Iwashima M, Dillon D, Harris S, Levy J. Headache. 2020 Apr; 60(4):701-712. Epub 2020 Jan 27.
- STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD(®) ) Device, in Healthy Adult Subjects.[Headache. 2019]STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD(®) ) Device, in Healthy Adult Subjects.Shrewsbury SB, Jeleva M, Satterly KH, Lickliter J, Hoekman J. Headache. 2019 Mar; 59(3):394-409. Epub 2019 Jan 19.
- A new dihydroergotamine nasal spray (Trudhesa) for migraine.[Med Lett Drugs Ther. 2021]A new dihydroergotamine nasal spray (Trudhesa) for migraine.. Med Lett Drugs Ther. 2021 Dec 27; 63(1640):204-207.
- Review MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.[Expert Opin Pharmacother. 2012]Review MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.Silberstein S. Expert Opin Pharmacother. 2012 Sep; 13(13):1961-8. Epub 2012 Aug 4.
- Review Ergotamine.[Drugs and Lactation Database (...]Review Ergotamine.. Drugs and Lactation Database (LactMed®). 2006
- Dihydroergotamine - Drugs and Lactation Database (LactMed®)Dihydroergotamine - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...